Moderna (MRNA) Interest Expenses (2018 - 2026)
Moderna (MRNA) posted quarterly Interest Expenses of $1.0 billion for Q2 2026, down 6.79% year-over-year from $1.1 billion in Q2 2025, and down 1.62% on a QoQ basis from $1.0 billion in Q1 2026.
Moderna (MRNA) Interest Expenses (2018 - 2026) Analysis & Trends
Moderna has reported Interest Expenses for 10 years, with the latest figure at $1.0 billion in Q2 2026.
- Interest Expenses for Q2 2026 came in at $1.0 billion, down 6.79% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 6.79% YoY), and the FY2025 annual result was $3.7 billion, up 21.21% from the prior year.
- Interest Expenses eased to $1.0 billion in Q2 2026, from $1.0 billion in the prior quarter.
- Over five years, Interest Expenses peaked at $3.1 billion in Q4 2024 and troughed at $4.0 million in Q4 2025.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2023, when Interest Expenses surged 1334.84%; it then tumbled 99.87% in 2025.
- A 5-year view of Interest Expenses shows it stood at $155.0 million in 2022, then surged by 1334.84% to $2.2 billion in 2023, then surged by 38.67% to $3.1 billion in 2024, then tumbled by 99.87% to $4.0 million in 2025, then surged by 25650.0% to $1.0 billion in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $1.0 billion in Q2 2026, $1.0 billion in Q1 2026, and $4.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 383.00 Mn |
| Mar 31, 2026 | 383.00 Mn |
| Sep 30, 2025 | 81.00 Mn |
| Sep 30, 2025 | 81.00 Mn |
| Jun 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.11 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Dec 31, 2024 | 3.08 Bn |
| Dec 31, 2024 | 3.08 Bn |
| Sep 30, 2024 | 1.16 Bn |
| Sep 30, 2024 | 1.16 Bn |
| Jun 30, 2024 | 1.17 Bn |
| Jun 30, 2024 | 1.17 Bn |
| Mar 31, 2024 | 1.18 Bn |
| Mar 31, 2024 | 1.18 Bn |
| Dec 31, 2023 | 2.22 Bn |
| Dec 31, 2023 | 2.22 Bn |